Analysts forecast that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will post sales of $27.26 million for the current quarter, Zacks reports. Two analysts have provided estimates for Enanta Pharmaceuticals’ earnings, with the highest sales estimate coming in at $30.56 million and the lowest estimate coming in at $23.97 million. Enanta Pharmaceuticals reported sales of $10.42 million in the same quarter last year, which would suggest a positive year over year growth rate of 161.6%. The firm is expected to report its next quarterly earnings report on Wednesday, February 14th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year sales of $27.26 million for the current year, with estimates ranging from $69.44 million to $97.28 million. For the next financial year, analysts forecast that the firm will post sales of $0.00 per share. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The business had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue was up 491.3% on a year-over-year basis.

A number of brokerages have commented on ENTA. Royal Bank of Canada cut shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 price target on the stock. in a research report on Tuesday. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. JMP Securities raised their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Finally, TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.25.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded down $0.71 during midday trading on Tuesday, reaching $57.97. 175,853 shares of the company’s stock were exchanged, compared to its average volume of 211,099. Enanta Pharmaceuticals has a twelve month low of $25.92 and a twelve month high of $59.88. The company has a market capitalization of $1,110.00, a PE ratio of 72.46 and a beta of 0.64.

Institutional investors have recently made changes to their positions in the business. GAM Holding AG purchased a new position in Enanta Pharmaceuticals during the second quarter valued at $108,000. Municipal Employees Retirement System of Michigan lifted its position in Enanta Pharmaceuticals by 3.5% during the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares during the period. SG Americas Securities LLC raised its position in shares of Enanta Pharmaceuticals by 5.8% in the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 237 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Enanta Pharmaceuticals by 62.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 1,702 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $220,000. 66.83% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/02/27-26-million-in-sales-expected-for-enanta-pharmaceuticals-inc-enta-this-quarter-2.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.